Focus: GE HealthCare is a diagnostic imaging and radiopharmaceutical company operating at scale with 743 active job openings, positioned as a global leader in medical imaging technologies and contrast agents.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Hot — 2969 jobs added in 30d
Net +2309 (2969 new, 660 removed). Aggressive expansion phase.
Best fit for imaging technologists, regulatory affairs, and commercial professionals; less attractive for small-molecule drug hunters unless interested in radiopharmaceuticals and diagnostics.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
X-ray contrast agent with approaching loss of exclusivity; core legacy product facing generic/biosimilar erosion.
Help build intelligence for GE HealthCare
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GE HealthCare's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Radiopharmaceutical kit formulation approaching LOE; limited clinical indication data available.
Nuclear medicine agent with approaching LOE; indication and mechanism not detailed in available data.
Established radiopharmaceutical for thyroid scintigraphy; absorbed and trapped by thyroid to assess function in normal and abnormal states.
Radiopharmaceutical chelate kit with approaching LOE; limited clinical context available.
MRI contrast agent with approaching LOE; core legacy product facing generic competition.
Diagnostic agent with approaching LOE; clinical use not detailed in available data.
Radiopharmaceutical diagnostic agent used for imaging; standard nuclear medicine tracer with established clinical role.
Nuclear imaging kit with approaching LOE; specific indication not provided in available data.
X-ray contrast agent with approaching LOE; core legacy product competing in commoditizing contrast market.
46 discontinued, 14 duplicate formulations not shown
Why GE HealthCare (GEHC) Is Doubling Down on Pharmaceutical Diagnostics? - Yahoo Finance
Why GE HealthCare (GEHC) Is Doubling Down on Pharmaceutical Diagnostics? Yahoo Finance
GE HealthCare to acquire SOFIE Biosciences for $945 million - DOTmed
GE HealthCare to acquire SOFIE Biosciences for $945 million DOTmed
GE HealthCare to acquire SOFIE Biosciences for $945 million, expanding U.S. PET supply footprint - Greater Milwaukee Today
GE HealthCare to acquire SOFIE Biosciences for $945 million, expanding U.S. PET supply footprint Greater Milwaukee Today
GE HealthCare to Acquire SOFIE Biosciences for $945 Mn - Digital Health News
GE HealthCare to Acquire SOFIE Biosciences for $945 Mn Digital Health News
GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million: - HedgeCo.Net
GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million: HedgeCo.Net
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal - TradingView
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal TradingView
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
RACS: An Integrated FMEA-HACCP Framework for Advanced Risk Assessment and Control in Regulated Industries.
Enhancing accuracy and precision of arterial cerebral blood volume imaging in patients with moyamoya disease: Integration of long-labeled long-delay acquisition into DANTE-prepared multi-delay arterial spin labeling.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo